Codexis Inc. (NASDAQ:CDXS) shares were up 1.4% during mid-day trading on Wednesday . The stock traded as high as $4.38 and last traded at $4.27, with a volume of 76,637 shares. The stock had previously closed at $4.21.

Several research analysts recently issued reports on CDXS shares. HC Wainwright started coverage on shares of Codexis in a report on Wednesday, June 1st. They set a “buy” rating and a $6.00 target price for the company. Zacks Investment Research raised shares of Codexis from a “sell” rating to a “hold” rating in a report on Wednesday, August 10th.

The stock’s market capitalization is $175.39 million. The firm’s 50-day moving average price is $4.21 and its 200-day moving average price is $3.83.

Codexis (NASDAQ:CDXS) last released its quarterly earnings results on Tuesday, August 9th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.09. The company earned $16 million during the quarter, compared to the consensus estimate of $15.10 million. The company’s quarterly revenue was up 166.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.14) EPS. Equities analysts expect that Codexis Inc. will post ($0.20) EPS for the current fiscal year.

In related news, major shareholder Ventures Fund Vii L.P. Vivo sold 86,894 shares of the company’s stock in a transaction dated Tuesday, August 16th. The stock was sold at an average price of $4.25, for a total transaction of $369,299.50. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Vivo Ventures Vii, Llc sold 50,000 shares of the company’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $4.27, for a total value of $213,500.00. The disclosure for this sale can be found here.

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.